整理 | GLP1减重宝典内容团队2月21日,美国监管机构表示,诺和诺德的减肥和糖尿病药物不再短缺,这一决定预计将限制大众获得廉价复合药的机会。诺和诺德研发的司美格鲁肽制剂长期供不应求,为了满足市场需求,复合制药公司通过组合、混合或改变药物成分的方式,复制这种药物。美国食品和药物管理局周五表示,诺和诺德现在可以满足全国范围内对 Ozempic 和 Wegovy(均为司美格鲁肽)的需求。这项裁决表明...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.